Plasma immune analytes in patients with epithelial ovarian cancer
Abstract
No abstract availableKeywords
Funding Information
- Mayo Clinic Ovarian Cancer SPORE
This publication has 40 references indexed in Scilit:
- The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumorsJournal of Ovarian Research, 2013
- Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic massGynecologic Oncology, 2012
- Hepatic acute phase proteins – Regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signalingEuropean Journal of Cell Biology, 2012
- The Utility of Human Epididymal Protein 4, Cancer Antigen 125, and Risk for Malignancy Algorithm in Ovarian Cancer and EndometriosisInternational Journal of Gynecological Cancer, 2012
- Interleukin-6 as a Therapeutic Target in Human Ovarian CancerClinical Cancer Research, 2011
- Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal studyAnnals of Oncology, 2011
- Transactivation of the Epidermal Growth Factor Receptor by Heat Shock Protein 90 via Toll-like Receptor 4 Contributes to the Migration of Glioblastoma CellsJournal of Biological Chemistry, 2011
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- Autoantibodies to Tumor-Associated Antigens in Epithelial Ovarian CarcinomaJournal of Oncology, 2009
- MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouseDifferentiation, 2008